NDAORALTABLET
Approved
Jul 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
NORVASC (amlodipine besylate) by Viatris is (calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. First approved in 1992.
Drug data last refreshed 2h ago · AI intelligence enriched 4h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVASC (amlodipine besylate) is an oral calcium channel blocker approved in 1992 for hypertension and angina. It works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, causing peripheral vasodilation and reducing blood pressure and myocardial oxygen demand. The drug selectively acts on vascular smooth muscle with minimal effects on cardiac contractility at therapeutic doses.
$0.016BPart D
LOE ApproachingDeclining
As LOE approaches, brand team focus shifts from growth to lifecycle extension and generic-to-brand transition management; smaller teams emphasize efficiency.
Mechanism of Action
(calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…
Indications
Worked on NORVASC at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.